JP2005524624A5 - - Google Patents

Claims (19)

A medicament comprising a therapeutically effective amount of at least one MAb that selectively binds to peptidoglycan (PepG) of gram positive bacteria, wherein the MAb provides a therapeutically beneficial result upon administration to a patient.   The medicament according to claim 1, wherein the administration reduces the number of gram-positive bacteria in the patient.   The medicament according to claim 1, wherein the at least one MAb binds to PepG of Gram-positive bacteria at a level at least twice as large as background in ELISA.   The medicament according to claim 1, wherein the at least one MAb enhances the opsonophagocytosis of Gram positive bacteria by at least 50%. 2. The medicament of claim 1 , further comprising a pharmaceutically acceptable carrier, at least one anti-staphylococcal drug, at least one MAb that binds lipoteichoic acid (LTA) of Gram-positive bacteria, or a combination thereof .   2. The medicament of claim 1, wherein the at least one MAb prevents colonization by gram positive bacteria upon instillation into the patient's nostril.   At least one MAb is Staphylococcus aureus, Staphylococcus epidermidis, Streptococus mutans, Bacillus subtilis, Bacillus megaterium, Enterococcus faecium The medicament according to claim 1, which specifically binds to PepG of a Gram positive bacterium selected from Enterococcus faecalis) and Listeria monocytogenes.   At least one MAb is selected from MAB-11-232.3, MAB-11-248.2, MAB-11-569.3, MAB-11-232.3 IE9, MAb-99-110FC12 IE4, A130 and M130. The pharmaceutical described.   2. The medicament of claim 1, wherein the at least one MAb comprises a variable region comprising a polypeptide having an amino acid sequence selected from SEQ ID NOs: 1 and 3.   2. The medicament of claim 1, wherein the at least one MAb comprises a variable region comprising a polypeptide having at least 80% identity with an amino acid sequence selected from SEQ ID NOs: 1 and 3.   The medicament according to claim 1, wherein the at least one MAb is selected from a chimeric MAb, a humanized MAb and a human MAb.   2. The medicament of claim 1, wherein at least one MAb comprises a modified Fc portion, wherein the modification reduces non-specific binding of the Mab through the Fc portion. The medicament according to claim 1, wherein the at least one MAb is selected from Fab, Fab ', F (ab') ₂ , Fv, SFv and SCFV. Use of the MAb of claim 1 in the manufacture of a medicament for treating a patient by administering a therapeutically effective amount. The patient is selected from hospitalized infants, premature babies, burn victims, elderly patients, immunocompromised patients, immunosuppressed patients, patients undergoing invasive procedures or health care workers 15. Use according to claim 14. Protective monoclonal antibodies are administered intravenously, intraperitoneally, intravitreal injection, intraarticular, intraventricular, intrathecal, intramuscular, subcutaneous, intranasal, depending on the selected route from the vaginal and oral, claim 14 Use as described in . Hybridoma cells deposited with ATCC under accession number PTA-2492 or PTA-3659 . A vaccine comprising at least one purified PepG, peptide, fragment or epitope thereof in a pharmaceutically acceptable carrier. Use of at least one purified PepG, peptide, fragment or epitope thereof in the manufacture of a medicament for providing a vaccination effect to a patient by administering a therapeutically effective amount.